EXHIBIT 10.1
ASSET PURCHASE
AGREEMENT
dated August 21,
2009
between
OHR PHARMACEUTICAL,
INC.
and
GENAERA LIQUIDATING
TRUST
Table of
Contents
|
|
ARTICLE
I CERTAIN DEFINITIONS; CONSTRUCTION
2
|
|
|
ARTICLE
II PURCHASE AND SALE OF
ASSETS
6
|
|
|
|
Purchase and
Sale of Assets
6
|
|
|
|
|
Certain
Rights of Seller
8
|
|
|
|
ARTICLE
III THE CLOSING
8
|
|
|
|
Delivery of
Items by the Seller
|
|
|
|
|
Delivery of
Items by the Purchaser
|
|
|
|
ARTICLE
IV REPRESENTATIONS AND WARRANTIES OF THE SELLER
9
|
|
|
|
Organization, Qualification and Power
|
|
|
|
|
Noncontravention; Governmental
Approvals .
|
|
|
|
|
Tangible
Personal Property; the Assets
|
|
|
|
ARTICLE
V REPRESENTATIONS AND WARRANTIES OF THE
PURCHASER
11
|
|
|
|
Noncontravention; Governmental
Approvals .
|
|
|
|
ARTICLE
VII INDEMNIFICATION
14
|
|
|
|
Indemnification Obligations
.
|
|
|
|
|
Method of
Asserting Claims
|
|
|
|
|
Further
Items Relating to Indemnification
|
|
|
|
ARTICLE
VIII MISCELLANEOUS
15
|
|
|
|
Press
Releases and Public Announcement
|
|
|
|
|
No
Third-Party Beneficiaries
|
|
|
|
|
Succession
and Assignment
|
|
|
|
|
CONSENT TO
JURISDICTION AND SERVICE OF PROCESS
|
|
EXHIBITS
Exhibit
A Form
of Bill of Sale and General Assignment
Exhibit
B Form
of Patent Assignment
Exhibit
C Form
of Trademark Assignment
Schedule
2.1(a) Intellectual
Property relating to Squalamine and all related analog compounds
and Trudosquemine and all related analog compounds
Schedule
2.1(b) Seller’s
tangible assets relating to Squalamine and all related analog
compounds and Trudosquemine and all related analog
compounds
Schedule
4.6 Description
of Squalamine Royalties
ASSET PURCHASE
AGREEMENT
This ASSET
PURCHASE AGREEMENT is dated August 21, 2009 (this “
Agreement ”) between OHR PHARMACEUTICAL,
INC., a Delaware corporation (formerly known as BBM Holdings, Inc.)
located at 1245 Brickyard Road, #590, Salt Lake City, Utah 84106
(the “Purchaser”), and GENAERA LIQUIDATING TRUST, a
Delaware trust located at Argyce LLC, Trustee for the Genaera
Liquidating Trust, 610 Second Street Pike, Southampton, PA 18966
(the “ Seller”)
PREAMBLE
WHEREAS, the Seller is a liquidating trust
formed pursuant to the Delaware General Corporation Law (the
“DGCL”) to dispose of all of the assets of Genaera
Corporation, a Delaware corporation dissolved pursuant to Section
274 of the DGCL ( the “Predecessor”), a
biopharmaceutical company formed to develop medicines to address
substantial unmet medical needs in major pharmaceutical markets
(the “ Business ”) and to wind up its affairs,
pay or adequately provide for the payment of all of its liabilities
and distribute to or for the benefit of its stockholders all of the
Predecessor’s assets, including interests in any liquidating
trust established in connection with the complete liquidation of
the Predecessor;
WHEREAS, the parties executed a Term Sheet dated
July 8, 2009, pursuant to which Purchaser has been provided access
to information available from Seller and third parties holding
Assets on behalf of Seller as well as personnel formerly employed
by Predecessor and the parties now desire to close the transaction
contemplated in the Term Sheet on the terms and conditions set
forth herein;
WHEREAS, Section 7.2(c) of the Liquidating Trust
Agreement provides: “As far as reasonably practicable, the
Trustee shall cause any written instrument creating an obligation
of the Trust Assets to include a reference to [the Liquidating
Trust] Agreement and to provide that neither the Beneficiaries, the
Trustee nor its agents shall be liable thereunder, and that the
other parties to such instrument shall look solely to the Trust
Assets for the payment of any claim [under such instrument] or the
performance thereof; provided that the omission of such provision
from any such instrument shall not render the Beneficiaries, the
Trustee or its agents liable, nor shall the Trustee be liable to
anyone for such omission.”;
WHEREAS, the Purchaser paid $50,000 (the “
Downpayment ”) to Seller on July 8, 2009;
and
WHEREAS, the Purchaser desires to purchase from
the Seller and the Seller desires to sell to the Purchaser certain
of the assets, and underlying intellectual property in connection
with the Business, which assets are further described
herein.
NOW, THEREFORE, in consideration of the
representations, warranties and covenants contained herein and for
other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto hereby agree
as follows:
ARTICLE I
CERTAIN DEFINITIONS;
CONSTRUCTION
1.1 Certain
Definitions .
(a) The following
terms, when used in this Agreement, shall have the respective
meanings ascribed to them below:
“ Action ” means any
litigation, claim, action, suit, inquiry, hearing, investigation or
other proceeding.
“ Affiliate ” means, with
respect to any Person, any other Person that, directly or
indirectly, through one or more intermediaries, Controls, is
Controlled by or is under common Control with, such
Person. For purposes of this definition, “
Control ” (including, with correlative meanings, the
terms “Controlled by” and “under common Control
with”) means the possession, directly or indirectly, of the
power to direct or cause the direction of the management or
policies of a Person, whether through the ownership of stock, as
trustee or executor, by Contract or credit arrangement or
otherwise. Without limitation on the foregoing, Genaera
Corporation shall be deemed an Affiliate of the Seller.
“ Agreement ” has the meaning
set forth in the preamble hereto.
“ Ancillary Agreements ”
means, collectively, the Bill of Sale and General Assignment, the
Trademark Assignment and the Patent Assignment.
“ Assets ” has the meaning
set forth in Section 2.1.
“ Bills of Sale ” has the
meaning set forth in Section 3.2(c).
“ Business ” has the meaning
set forth in the preamble hereto.
“ Business Day ” means any
day other than Saturday, Sunday or any day on which banks in
New York, New York are required or authorized to be
closed.
“ China License Rights ” -
shall mean (i) such of the Assets as include the right to
manufacture, compound, deliver, license, use, sell or otherwise
deal in Squalamine and related analog compounds and Trodusquemine
and related analog compounds, and precursors of any of the
foregoing, solely within China (and not for export from China or
import into China) and (ii) the right of Seller to approve or
disapprove of any transaction involving or affecting any of such
Assets.
“ Claim Notice ” means
written notification pursuant to Section 7.2(a) of a Third-Party
Claim as to which indemnity pursuant to Section 7.1 is sought by an
Indemnified Party.
“ Closing ” has the meaning
set forth in Section 3.1.
“ Closing Date ” has the
meaning set forth in Section 3.1.
“ Code ” means the Internal
Revenue Code of 1986, as amended, and the rules and regulations
promulgated thereunder.
“ DGCL ” has the meaning set
forth in the preamble hereto.
“ Excluded Assets ” has
the meaning set forth in Section 2.2.
“ GAAP ” means United States
generally accepted accounting principles as in effect from time to
time, consistently applied throughout the specified period and all
prior comparable periods.
“ Governmental Entity ” means
any government or political subdivision thereof, whether foreign or
domestic, federal, state, provincial, county, local, municipal or
regional, or any other governmental entity, any agency, authority,
department, division or instrumentality of any such government,
political subdivision or other governmental entity, any court,
arbitral tribunal or arbitrator, and any nongovernmental regulating
body to the extent that the rules, regulations or orders of such
body have the force of Law.
“ Indemnified Party ” means
any Person claiming indemnification under any provision of Article
VII.
“ Indemnifying Party ” means
any Person against whom a claim for indemnification is being
asserted under any provision of Article VII.
“ Intellectual Property ”
means such of the Assets as includes: all
(i) discoveries and inventions (whether patentable or
unpatentable and whether or not reduced to practice), patents,
patent applications (either filed or in preparation for filing) and
statutory invention registrations, including reissues, divisions,
continuations, continuations in part, extensions and reexaminations
thereof, all rights therein provided by international treaties or
conventions, and all improvements thereto, (ii) trademarks,
service marks, trade dress, logos, trade names, corporate names,
and other source identifiers (whether or not registered) including
all common law rights, and registrations and applications for
registration (either filed or in preparation for filing) thereof,
all rights therein provided by international treaties or
conventions, and all reissues, extensions and renewals of any of
the foregoing, (iii) copyrightable works, copyrights (whether
or not registered) and registrations and applications for
registration thereof (either filed or in preparation for filing),
all rights therein provided by international treaties or
conventions, and all extensions and renewals of any of the
foregoing, (iv) confidential and proprietary information,
trade secrets, know-how (whether patentable or unpatentable and
whether or not reduced to practice), processes and techniques, and
research and development information, ideas, technical data,
designs, drawings and specifications and associated goodwill,
remedies against infringements thereof and rights of protection of
an interest therein under the Laws of all applicable jurisdictions,
and (viii) copies and tangible embodiments of any item described in
the foregoing.
“ Knowledge ”, “
Known ” and words of similar import mean the actual
knowledge of the Trustee.
“ Laws ” means all laws,
statutes, rules, regulations, ordinances and other pronouncements
having the effect of law of the United States, any domestic or
foreign state, county, city or other political subdivision or of
any Governmental Entity.
“ Liability ” means all
indebtedness, obligations and other liabilities of a Person,
whether absolute, accrued, contingent, fixed or otherwise, and
whether due or to become due.
“ Lien ” means any mortgage,
pledge, assessment, security interest, lease, lien, adverse claim,
levy, charge or other encumbrance of any kind, whether voluntary or
involuntary (including any conditional sale Contract, title
retention Contract or Contract committing to grant any of the
foregoing). For the avoidance of doubt, the China
License Rights shall not be considered a “Lien” under
this Agreement.
“Liquidating Trust Agreement
” means the Agreement and
Declaration of Trust dated as of June 12, 2009, by and among the
Predecessor and Argyce LLC, a Delaware limited liability company,
as Trustee.
“ Loss ” means any and all
damages, fines, fees, penalties, deficiencies, losses and expenses
(including all interest, court costs, fees and expenses of
attorneys, accountants and other experts or other expenses of
litigation or other proceedings or of any claim, default or
assessment or pursuit of rights to indemnification).
“ Material Adverse Effect ”
means any material adverse effect on the condition (financial or
otherwise), operations, business, prospects, assets or results of
operations of the Business.
“ Order ” means any
writ, judgment, decree, injunction or similar order of any
Governmental Entity (in each case whether preliminary or
final).
“ Patent Assignment ” has the
meaning set forth in Section 3.2(d).
“ Person ” means any
individual, general or limited partnership, limited liability
company, corporation, association, joint stock company, trust,
estate, joint venture, unincorporated organization, Governmental
Entity or any other entity of any kind.
“ Predecessor ” has the
meaning set forth in the preamble hereto.
“ Purchase Price ” has the
meaning set forth in Section 2.4.
“ Purchaser ” has the meaning
set forth in the preamble hereto.
“ Recipients ” has the
meaning set forth in Section 6.4.
“ Representatives ” means,
with respect to any Person, the directors, officers, partners,
employees, counsel, accountants and other authorized
representatives of such Person.
“ Resolution Period ” means
the period ending thirty days following receipt by an Indemnified
Party of a Dispute Notice.
“ Retained Liabilities ” has
the meaning set forth in Section 2.3.
“ Seller ” has the meaning
set forth in the preamble hereto.
“ Seller ” has the meaning
set forth in the preamble hereto.
“ Tax Returns ” means all
returns and reports (including elections, claims, declarations,
disclosures, schedules, estimates, computations and information
returns) required to be supplied to a Taxing Authority in any
jurisdiction relating to Taxes.
“ Taxes ” means all United
States federal, state, local and foreign income, profits,
franchise, gross receipts, environmental, customs duty, capital
stock, severance, stamp, payroll, sales, employment, unemployment,
disability, use, property, withholding, excise, production, value
added, occupancy and other taxes, duties or assessments of any
nature whatsoever together with all interest, penalties, fines and
additions to tax imposed with respect to such amounts and any
interest in respect of such penalties and additions to
tax.
“ Taxing Authority ” means
any governmental agency, board, bureau, body, department or
authority of any United States federal, state or local jurisdiction
or any foreign jurisdiction, having or purporting to exercise
jurisdiction with respect to any Tax.
“ Third-Party Claim ” has the
meaning set forth in Section 7.2(a).
“ Trademark Assignment ” has
the meaning set forth in Section 3.2(e).
“ Transfer Taxes ”
means sales, use, value added, excise, registration, documentary,
stamp, transfer, real property transfer, recording, gains, stock
transfer and other similar Taxes and fees.
“ Trust ” has the meaning set
forth in the preamble hereto.
“ Trustee ” means Argyce LLC,
a Delaware limited liability company, as trustee of the Trust under
the Liquidating Trust Agreement, and any successor trustee
thereunder.
(b)
Construction . For purposes of this Agreement,
except as otherwise expressly provided herein or unless the context
otherwise requires: (i) words using the singular or
plural number also include the plural or singular number,
respectively, and the use of any gender herein shall be deemed to
include the other genders; (ii) references herein to
“Articles,” “Sections,”
“subsections” and other subdivisions, and to Exhibits,
Schedules, Annexes and other attachments, without reference to a
document are to the specified Articles, Sections, subsections and
other subdivisions of, and Exhibits, Schedules, Annexes and other
attachments to, this Agreement; (iii) a reference to a
subsection without further reference to a Section is a
reference to such subsection as contained in the same Section
in which the reference appears, and this rule shall also apply to
other subdivisions within a Section or subsection; (iv) the
words “herein,” “hereof,”
“hereunder,” “hereby” and other words of
similar import refer to this Agreement as a whole and not to any
particular provision; (v) the words “include,”
“includes” and “including” are deemed to be
followed by the phrase “without limitation”; and (vi)
all accounting terms used and not expressly defined herein have the
respective meanings given to them under GAAP.
(c) Preamble .
The Preamble set forth above is part of this Agreement.
ARTICLE II
PURCHASE AND SALE OF
ASSETS
2.1 Purchase and
Sale of Assets . Upon the terms and conditions set
forth in this Agreement, and in consideration of the payment by the
Purchaser of the Purchase Price, the Seller shall sell, convey,
transfer, assign, grant and deliver to the Purchaser, and the
Purchaser shall purchase, acquire and accept from the Seller, at
the Closing, all right, title and interest in and to the following
assets and properties of every kind, nature, character and
description (whether tangible or intangible, whether absolute,
accrued, contingent, fixed or otherwise and wherever situated),
including the goodwill related thereto (collectively, the “
Assets ”), free and clear of all Liens:
(a) the Seller’s
Intellectual Property relating to Squalamine and all related analog
compounds and Trudosquemine and all related analog compounds
including those set forth on Schedule 2.1(a)
(b) the Seller’s
tangible assets relating to Squalamine and all related analog
compounds and Trudosquemine and all related analog compounds,
including those set forth on Schedule 2.1(b)
;
(c)
the Seller’s records of the development of
Squalamine and related analog compounds and Trodusquemine and
related analog compounds including lab notebooks, FDA filings and
correspondence, research reports, research and clinical data,
manufacturing and production records, and patent
correspondence.
2.2
Excluded Assets
. Notwithstanding
anything in this Agreement to the contrary, all tangible and
intangible property not described in Section 2.1 (the “
Excluded Assets ”) shall be excluded from, and shall
not constitute, Assets. Without limiting the generality
of the immediately preceding sentence, the Excluded Assets include
the following:
(a) all intellectual
property and tangible assets of the Seller relating to the IL-9
development program with Medimmune;
(b) all intellectual
property and tangible assets of the Seller relating to the
pexiganan development program;
(c) all intellectual
property and tangible assets of the Seller relating to the
talniflumate (“Lomucin”) development
program;
(d) the
inventory of Squalamine previously sold to Georgetown
University as per the Bill of Sale signed by
the Predecssoron June 5, 2009;
(e) cash, commercial
paper, certificates of deposit, bank deposits, treasury bills and
other cash equivalents;
(f) all insurance
policies relating to the operation of the Business;
(g) all of the
Seller’s right, title and interest in and to Tax credits and
prepaid Taxes;
(h) all assets owned
or held by any employee benefit plan;
(j) all real property
owned or leased by the Seller;
(k) the organizational
books and records of the Seller;
(l) all of the
Seller’s right, title and interest in and to this
Agreement;
(m) the China License
Rights; and
(n) all claims or
causes of action, except those directly related to the
Assets.
2.3 Retained
Liabilities . The Purchaser assumes no Liabilities
relating to the Business, the Assets or the Seller. All
such Liabilities (collectively, the “ Retained
Liabilities ”), are, and shall at all times remain, the
Liabilities of the Seller.
2.4 Purchase
Price . The Purchaser shall pay to the Seller the
aggregate amount of $200,000 (the “ Purchase Price
”), of which $50,000 was previously paid as the Downpayment
and the balance of $150,000 shall be paid at the Closing by wire
transfer of immediately available funds. The Seller and the
Purchaser shall each report federal, state, local and other Tax
consequences of the purchase and sale contemplated hereby
(including the filing of Internal Revenue Service
Form 8594).
2.5 Third Party
Consents . To the extent that any of the Assets is
not assignable without the consent, waiver or approval of another
Person and such consent, waiver or approval has not been obtained
before or at the Closing, this Agreement shall not constitute an
assignment or an attempted assignment of such Asset by the Seller
or an assumption or an attempted assumption of such Asset by the
Purchaser. The Seller shall use its commercially
reasonable efforts to obtain such consents, waivers and approvals
as soon as practicable following the date hereof and the Purchaser
shall cooperate with and assist the Seller to this end;
provided , however , that the Seller shall take no
action to seek such consent, waiver or approval without prior
consultation with or approval by the Purchaser and no party shall
be required to pay any sums in connection therewith. If
any such consent, waiver or approval shall not be obtained before
or at the Closing, then until such consent, waiver or approval is
obtained, the Seller shall cooperate with the Purchaser in any
reasonable arrangement designed to provide the Purchaser with the
benefits intended to be assigned to the Purchaser with respect to
the underlying Asset.
2.6 Certain Rights
of Seller. Seller retains all right, title and
interest in and to the China License Rights provided however that
Seller shall not license or otherwise transfer China License Rights
unless it has first conferred with Purchaser as to the terms and
conditions of said license and transfer and obtained
Purchaser’s prior written consent. In the event that Seller
or Purchaser, or any of their affiliates, receive or become aware
of a bona fide offer to purchase or license those Assets subject to
the China License Rights, Seller shall consider in good faith terms
by which such purchase or license can be consummated. Seller now
exp